Madrigal Pharmaceuticals (MDGL) Receivables - Net (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 4 years of Receivables - Net data on file, last reported at $187.4 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 205.0% year-over-year to $187.4 million in Q1 2026; TTM through Mar 2026 was $187.4 million, a 205.0% increase from a year earlier, with the FY2025 full-year figure at $134.5 million, up 149.85% from the prior year.
• Receivables - Net for Q1 2026 stood at $187.4 million, up from $134.5 million in the prior quarter.
• Over the last five years, Receivables - Net for MDGL reached as high as $187.4 million in Q1 2026 and fell as low as $6.9 million in Q2 2024.
• Historically, Receivables - Net has averaged $83.4 million across 3 years, with a median of $70.3 million in 2025.
• On a YoY basis, Receivables - Net climbed as much as 1048.44% in 2025 and fell as far as 149.85% in 2025.
• Year by year, Receivables - Net stood at $53.8 million in 2024, then surged by 149.85% to $134.5 million in 2025, then soared by 39.32% to $187.4 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $187.4 million in Q1 2026, $134.5 million in Q4 2025, and $113.3 million in Q3 2025.